<iframe src="//www.googletagmanager.com/ns.html?id=GTM-MX3DVL" height="0" width="0" style="display:none;visibility:hidden"></iframe>Pestalozzi advised Johnson & Johnson's Swiss based Cilag International on its acquisition of Covagen AG | Pestalozzi Attorneys at Law

Pestalozzi advised Johnson & Johnson's Swiss based Cilag International on its acquisition of Covagen AG

08.2014

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAbtechnology platform. Covagen's lead product, COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb®, is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. Pestalozzi advised Cilag GmbH International on all Swiss legal and tax aspects of the acquisition.

To the top